What Drugs Work Like Tigecycline?
Tigecycline, sold as Tygacil, is a glycylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It treats complicated skin/skin structure infections, intra-abdominal infections, and community-acquired pneumonia, with broad activity against multidrug-resistant gram-positive, gram-negative, and anaerobic bacteria.[1]
Drugs with similar function include other glycylcyclines and tetracyclines that target the same ribosomal site, though tigecycline has enhanced potency against resistant strains.
Closest Alternatives: Other Glycylcyclines
- Eravacycline (Xerava): A synthetic fluorocycline structurally related to tigecycline. It binds the 30S ribosome like tigecycline, resisting efflux pumps and ribosomal protection. FDA-approved for complicated intra-abdominal infections caused by gram-negative pathogens, including resistant Acinetobacter and Enterobacteriaceae. Dosed IV at 1 mg/kg every 12 hours.[1][2]
No other glycylcyclines are widely available; eravacycline is the only direct structural analog currently marketed.
Tetracyclines with Overlapping Mechanisms
These bind the 30S ribosome similarly but are less effective against some tigecycline-susceptible resistant bugs:
- Doxycycline: Oral/IV option for skin/soft tissue infections, respiratory tract infections, and rickettsial diseases. Broader outpatient use than tigecycline.
- Minocycline: Stronger against MRSA and some gram-negatives; used for skin infections and acne.
- Omadacycline (Nuzyra): Modern aminomethylcycline with tigecycline-like ribosomal binding and resistance evasion. FDA-approved for community-acquired bacterial pneumonia and acute skin infections; available oral/IV.[1][3]
How Do They Compare Head-to-Head?
| Drug | Spectrum vs. Tigecycline | Key Uses | Dosing Notes | Resistance Edge |
|------|---------------------------|----------|--------------|-----------------|
| Eravacycline | Nearly identical (stronger vs. some Enterobacterales) | cIAI only | Lower doses, less nausea | Similar efflux resistance |
| Omadacycline | Comparable gram+; slightly weaker gram- | CABP, cSSSI | Oral switch possible | Good vs. MRSA, S. aureus |
| Doxycycline | Weaker vs. Pseudomonas, Acinetobacter | Broader outpatient | Oral preferred | Less reliable vs. MDR |
Tigecycline covers more anaerobes but has higher mortality risk in some ventilator-associated pneumonia trials, leading to boxed warnings.[1][4]
When Are These Prescribed Instead?
Physicians switch to eravacycline or omadacycline for lower GI toxicity (tigecycline causes nausea/vomiting in 20-30% of patients). Tetracyclines like doxycycline are cheaper for outpatient step-down therapy. All share black-box warnings for tooth discoloration in kids under 8.[4]
Patent and Availability Notes
Tigecycline's key patents expired in 2016-2021 in major markets, enabling generics.[5] Eravacycline patents run to 2033; omadacycline to 2031 (check DrugPatentWatch.com for updates).[5]
[1] FDA Label: Tygacil (tigecycline). https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/021821s021lbl.pdf
[2] FDA Label: Xerava (eravacycline). https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/021361s000lbl.pdf
[3] FDA Label: Nuzyra (omadacycline). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816lbl.pdf
[4] ClinicalInfo: Tetracyclines overview. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/tetracyclines
[5] DrugPatentWatch.com: Tigecycline patents. https://www.drugpatentwatch.com/p/tradename/TYGACIL